Reviewer's report
Title:Mucosal gene therapy using a pseudotyped lentivirus vector encoding
murine interleukin-10 (mIL-10) suppresses the development and relapse of
experimental murine colitis
Version:2Date:11 February 2014
Reviewer: Suy Somanathan
Reviewer's report:
1) Major Compulsory Revisions
In the discussions, the authors claim the success of being able to administer two
doses of the lentiviral vector. However, even one dose was sufficient to correct
the phenotype of DSS induced colitis. Given that how can the authors claim any
contribution from the second vector administration?
Moreover, the level of IL-10 did not change after the second vector. The authors
provide an explanation that the levels of endogenous IL-10 may have gone down
to which may keep the levels of IL-10 the same.
However, what if there was a humoral immune response to the first vector
administration that blocked the second vector. In this case the authors would still
get the same level of protection, since one vector administration was sufficient to
protect, and as expected the levels of IL-10 would not change.
So either the authors have to provide evidence that the second vector
administration was successful or discuss the possibility that the second
administration could have failed.
2) Major Compulsory Revisions
Have the authors measured IL-10 levels in serum? Did they change? And what
effect if any does LVmIL-10 expression have on any other immune response in
the animal? For instance, would we expect immunity to be compromised against
a pathogen by this approach? The authors could easily measure the B or T cell
responses against some commonly available antigens after the LVmIL10
treatment. Or at least the potential for such issues should be discussed.
Level of interest: An article whose findings are important to those with closely
related research interests
Quality of written English: Acceptable
Statistical review: No, the manuscript does not need to be seen by a statistician.
Declaration of competing interests:
I declare that I have no competing interests
Reviewer's report
Title:Mucosal gene therapy using a pseudotyped lentivirus vector encoding
murine interleukin-10 (mIL-10) suppresses the development and relapse of
experimental murine colitis
Version:2Date:11 February 2014
Reviewer: Suy Somanathan
Reviewer's report:
1) Major Compulsory Revisions
In the discussions, the authors claim the success of being able to administer two
doses of the lentiviral vector. However, even one dose was sufficient to correct
the phenotype of DSS induced colitis. Given that how can the authors claim any
contribution from the second vector administration?
Moreover, the level of IL-10 did not change after the second vector. The authors
provide an explanation that the levels of endogenous IL-10 may have gone down
to which may keep the levels of IL-10 the same.
However, what if there was a humoral immune response to the first vector
administration that blocked the second vector. In this case the authors would still
get the same level of protection, since one vector administration was sufficient to
protect, and as expected the levels of IL-10 would not change.
So either the authors have to provide evidence that the second vector
administration was successful or discuss the possibility that the second
administration could have failed.
2) Major Compulsory Revisions
Have the authors measured IL-10 levels in serum? Did they change? And what
effect if any does LVmIL-10 expression have on any other immune response in
the animal? For instance, would we expect immunity to be compromised against
a pathogen by this approach? The authors could easily measure the B or T cell
responses against some commonly available antigens after the LVmIL10
treatment. Or at least the potential for such issues should be discussed.
Level of interest: An article whose findings are important to those with closely
related research interests
Quality of written English: Acceptable
Statistical review: No, the manuscript does not need to be seen by a statistician.
Declaration of competing interests:
I declare that I have no competing interests
Please review this paper.
user
Reviewer's report
Title:Mucosal gene therapy using a pseudotyped lentivirus vector encoding
murine interleukin-10 (mIL-10) suppresses the development and relapse of
experimental murine colitis
Version:2Date:11 February 2014
Reviewer: Suy Somanathan
Reviewer's report:
1) Major Compulsory Revisions
In the discussions, the authors claim the success of being able to administer two
doses of the lentiviral vector. However, even one dose was sufficient to correct
the phenotype of DSS induced colitis. Given that how can the authors claim any
contribution from the second vector administration?
Moreover, the level of IL-10 did not change after the second vector. The authors
provide an explanation that the levels of endogenous IL-10 may have gone down
to which may keep the levels of IL-10 the same.
However, what if there was a humoral immune response to the first vector
administration that blocked the second vector. In this case the authors would still
get the same level of protection, since one vector administration was sufficient to
protect, and as expected the levels of IL-10 would not change.
So either the authors have to provide evidence that the second vector
administration was successful or discuss the possibility that the second
administration could have failed.
2) Major Compulsory Revisions
Have the authors measured IL-10 levels in serum? Did they change? And what
effect if any does LVmIL-10 expression have on any other immune response in
the animal? For instance, would we expect immunity to be compromised against
a pathogen by this approach? The authors could easily measure the B or T cell
responses against some commonly available antigens after the LVmIL10
treatment. Or at least the potential for such issues should be discussed.
Level of interest: An article whose findings are important to those with closely
related research interests
Quality of written English: Acceptable
Statistical review: No, the manuscript does not need to be seen by a statistician.
Declaration of competing interests:
I declare that I have no competing interests
assistant